In the summer of 1997, the first meeting on 'Acute Leukemias with Structurally Altered Core Binding Factor Subunits' was held. During the meeting, which attracted more than 140 participants, many recognized experts in the field of CBF and leukemia were present. In this short report we summarize new data on CBF involvement in leukemia and other diseases that were presented during the meeting.
Introduction
Core binding factor (CBF), also known as polyoma enhancer binding protein 2, is a transcription factor complex that consists of an ␣-and ␤-unit ( Figure 1 ). By binding DNA, CBF regulates the expression of many genes, some of which are involved in hematopoiesis (eg GM-CSF and M-CSFR, see Figure 1) . To date, three different human CBF␣ and one CBF␤ encoding genes have been identified (Table 1 ). The t(8;21)(q22;q22), inv(16)(p13q22) and t(12;21)(p12;q22) are frequently occurring chromosome aberrations in acute leukemias. All of these rearrangements lead to gene fusions that cause structural alterations of different subunits of the CBF protein complex (Figure 1) . One of the CBF␣ unit encoding genes, AML1, is fused to the ETO gene by the t(8;21). The CBF␤ encoding CBFB gene is fused to the MYH11 gene by the inv(16). Moreover, the t(12;21) results in a fusion of the
Figure 1
Cartoon of the CBF protein. CBF␣ binds DNA. CBF␤ does not bind DNA but stabilizes the DNA binding action of CBF␣. The AML1 (CBF␣2) gene is disrupted by the t(8;21) and t(12;21). The CBFB (CBF␤) gene is disrupted by the inv(16). The t(8;21) and inv(16) may account for as much as 20% of AML, whereas the t(12;21) is found in approximately 25% of childhood ALL. Genes regulated by CBF include the granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor receptor (M-CSFR), T cell receptor-␣, -␤, -␦ and -␥ (TCR␣, -␤, -␦, -␥), CD36 (cell surface glycoprotein), interleukin-3 (IL-3), granzyme B (GRZB), myeloperoxidase (MPO), neutrophil elastase (NE) and metastasis specific 1 (mts1) genes.
Correspondence: BA van der Reijden, Institute of Hematology, Erasmus University Rotterdam, PO Box 1738, 3000 DR, The Netherlands; Fax: 31 10 4362315 Table 1 Comparison of CBF/PEBP2 subunit nomenclature PEBP2 CBF AML HUGO gene symbol
Since several groups simultaneously identified CBF subunits, they have different names (PEBP2, CBF or AML1-3), resulting in a complex nomenclature. The right column gives the names of the three different human encoding CBF␣ and CBF␤ genes approved by the HUGO nomenclature committee.
TEL and AML1 genes ( Table 2) . Apart from these frequently occurring aberrations, at least six other translocations affecting the AML1 gene have been identified in various types of leukemia (Table 2) . 
Clinical
The relatively good prognosis of leukemias with mutations in CBF subunit genes currently allows stratification of patients for different treatment protocols. Dr Burnett presented a large MRC trial and showed that allogeneic bone marrow transplantation for t(8;21) or inv(16) patients in first remission did not enhance disease-free survival. In this study, t(8;21) and inv(16) patients in first relapse had a significantly higher probability (69% and 83%, respectively) of achieving a second complete remission when compared to leukemias with a normal karyotype (40%). Based on these data, Dr Burnett concluded that a BMT should not be considered as initial choice of therapy in t(8;21) and inv(16) patients (abstract 6). Additional genetic lesions, including p-arm deletions in inv(16) cases, do not appear to alter the prognosis of t(8;21) and inv(16) leukemias (abstracts 6 and 23).
Long-term follow-up from a large Cancer and Leukemia Group B study, presented by Dr Bloomfield, showed that t(8;21) and inv(16) leukemias were more responsive to highdose cytarabine (HiDAC) than other AMLs (abstract 5). In particular for t(8;21) leukemias, HiDAC was shown to be an essential component of treatment. A 15-year follow-up analysis of the Fourth International Workshop of Chromosomes in Leukemia in a cohort of patients in which HiDAC was not administered in first remission, shows that the 10-year continuous complete remission (CCR) rates were 43% for inv(16) and 0% for t(8;21) patients. This is strikingly different from the CCR rates for inv(16) and t(8;21) patients (67% and 89%, respectively) obtained in comparable trials in which HiDAC is administered (abstract 5).
Finally, provocative preliminary data, presented by Dr Meyer-Monard, suggested that rhG-CSF may have antileukemic activity in de novo t(8;21) AML (abstracts 9 and 32). Exploration of this approach in relapsing patients may be interesting.
Minimal residual disease (MRD)
Studies on MRD were mainly focussed on CBFB-MYH11 follow-up detection. Drs Moos and Jäger showed that CBFB-MYH11 transcripts become undetectable after therapy in most patients, usually 10 to 12 months after presentation. In some cases of inv(16), cells expressing CBFB-MYH11 persist in the bone marrow. However, this is not predictive of relapse. It was generally agreed that MRD quantification may be the only way to reliably predict relapses in inv(16) cases. In support of this, by applying semi-quantitative RT-PCR, Dr Jäger showed in a limited series of inv(16) patients (n = 7) that a 2-log decrease of CBFB-MYH11 transcripts after induction therapy correlated with relapse, whereas larger decreases (4 logs) correlated with a durable complete remission (abstract 21). These promising results should now be confirmed in prospective studies.
Dr Drabkin presented a new approach to detect AML1-ETO-positive cells by using two sets of probes (one set on chromosome 8, the other on 21) in two-color FISH. Although the sensitivity of this method does not approach that of RT-PCR, it allows quantification of MRD at the cellular level (abstract 38).
Molecular and cellular biology of CBF, CBF fusion partners and CBF fusion proteins
The phenotypes of AML1-ETO and Cbfb-MYH11 knock-in, and AML1 and Cbfb knock-out mice were reviewed by Drs Liu, Speck and Downing. The knock-in and knock-out mice have very similar phenotypes: impairment of fetal liverderived definitive hematopoiesis, massive bleeding in the central nervous system and embryonic lethality around day 12.5-13.5 after gestation. These results suggest that the CBF fusion proteins influence normal CBF functioning in a dominantnegative way. However, the premature death of the knock-in mice hampers the in vivo study on the leukemogenic effect of the fusion proteins. To circumvent this problem, Dr Liu is currently making Cbfb-MYH11 knock-in mice with a conditional expression. Dr Downing showed that primitive hematopoietic cells from AML1-ETO embryos can be cultured in vitro for multiple passages. This suggests that the AML1-ETO fusion protein has transforming properties, and that these cells can be used to study the function of the AML1-ETO fusion protein in vitro.
The transforming properties of CBF fusion proteins may be caused by affecting normal CBF regulated gene expression. Dr Nucifora showed with in vitro experiments that CBF transcrip-tion regulation from the M-CSFR promoter is affected by the AML1-ETO fusion protein. In addition, Dr Cohn showed that the first intron of the metastasis-specific gene 1 (mts1) contains a CBF core site through which a reporter gene can be transactivated (abstract 10). It is not yet known whether CBF fusion proteins alter the expression of these genes in vivo, and whether this contributes to leukemogenesis. More insight into the pathogenesis of the leukemias will possibly be obtained by identifying additional CBF target genes that play a crucial role in hematopoietic cell differentiation and proliferation.
Dr Speck presented new data on the biochemical properties of CBF. She showed that DNA bends upon binding of CBF␣. After binding of CBF␤, a conformational change is observed in the CBF complex, while the DNA conformation is not further changed. Although the functional consequences of these conformational changes are unclear at present, only the first 141 aa of CBF␤ are required for these properties. Preliminary results show that the truncated 141 aa CBF␤ subunit, like the normal 182 and 187 aa isoforms, is sufficient to rescue primitive hematopoiesis in Cbfb knock-out mice. The role of the different CBF␤ C-termini, present in the normal 182 and 187 aa CBF␤ isoforms remains unknown.
New data were presented on the cellular localization and expression of CBF, its fusion partners, and fusion proteins. By using immunofluorescence, Dr Poirel showed that AML1 and TEL-AML1 colocalize in nuclear speckles in the leukemic cells of t(12;21) patients. In all cases tested, endogenous TEL was undetectable, regardless of whether the unaffected TEL allele was deleted or not (abstract 39). Another AML1 fusion partner, ETO, was shown to be expressed in brain tissue (abstract 41). In neurons, the ETO protein is located in the nucleus as well as in the cytoplasm.
Dr Ito presented new data on CBF directed myeloid differentiation. He presented a new AML1 splice variant, AML1⌬N. Unlike all other AML1 isoforms, AML1⌬N is unable to bind CBF␤ or DNA. Surprisingly, like the AML1a isoform, this new isoform also blocks myeloid differentiation. In contrast, the other AML1 isoforms (AML1b and AML1c) promote differentiation. The new isoform may play a role in the fine tuning of CBF function. Dr Ito showed that the activity of CBF may further be regulated by Ear-2, a member of the nuclear receptor superfamily. Ear-2 interacts with AML1, directly downstream of the DNA and CBF␤ binding runt domain. During myeloid differentiation Ear-2 expression is downregulated while AML1 expression remains unaltered. Ectopic expression of Ear-2 blocks myeloid differentiation. Apparently, Ear-2 interferes with AML1 controlled induction of myeloid differentiation. The AML1-ETO fusion protein blocks myeloid differentiation of 32Dcl3 cells (abstract 1), and inhibits erythroid differentiation of TF-1 cells (abstract 31). Because the AML1-ETO fusion protein is devoid of the Ear-2 interaction domain, it probably escapes Ear-2 regulation (abstract 1).
In addition to leukemia, CBF is also involved in other diseases. Dr Cameron presented evidence that the murine AML3 gene is involved in lymphomagenesis by retroviral insertion activation (abstract 35). Dr Otto showed that AML3 knock-out mice die shortly after birth due to respiratory failure. Because these mice have no bone, Dr Otto concluded that AML3 is also essential for bone formation (abstract 37). Heterozygous AML3 mice exhibit specific skeletal abnormalities strongly resembling those observed in patients with the inheritable disease cleidocranial dysplasia (CCD). Interestingly, Dr Otto showed that CCD was caused by AML3-inactivating mutations in the AML3 gene (abstract 37).These exciting discoveries show that AML3 is involved in both oncogenesis as well as congenital disease.
Conclusions
To date, CBF is the most frequently structurally altered protein in acute leukemia. Apart from its key role in normal and malignant blood cell formation, we now know that CBF is also essential for bone formation. The extension of the presented work will give a further understanding of the clinicopathological behavior of leukemias with structurally altered core binding factor subunits. Together with improved tools for diagnostics, this should lead to better clinical results in the future. At the end of the meeting Dr Hogge was awarded with the Leukemia poster prize. A description of her work is presented. All participants agreed that the concentration of both clinical and non-clinical data on one specific topic made this meeting a success. Plans are already being made for a second meeting.
Cytokine responsiveness of primitive progenitors in acute myelogenous leukemia DE Although it is well known that a proportion of malignant cells from patients with acute myelogenous leukemia (AML) will form colonies in semisolid media (AML CFC) only recently has it been possible to identify more primitive leukemic progenitor populations that give rise to long-term malignant hematopoiesis in vitro (AML long-term culture-initiating cells or LTC-IC) or in vivo in immunodeficient mice (SCID leukemia-initiating cells or SL-IC).
1,2 The identification of AML LTC-IC and SL-IC suggests that a hierarchy of progenitor cells exists in AML which is similar to that seen in normal hematopoiesis. In our laboratory we have been focusing our attention firstly, on using the LTC-IC and SL-IC assays to detect and quantitate leukemic progenitors and subsequently on using these assays to characterize some of the biological variability seen in the different subtypes of AML.
In initial LTC studies, we used our experience in optimizing these cultures for the detection of normal LTC-IC to develop a sensitive assay for analogous leukemic cells. 1, 3 In 5-weekold co-cultures of AML cells with pre-established, irradiated feeder layers we were able to detect cytogenetically abnormal LTC-IC in nine of 10 leukemic samples tested including all three with the inv(16) abnormality. At limiting dilution the frequency of these LTC-IC was 10 to 300-fold lower than that of AML CFC in the same sample. Interestingly, in every case we were also able to detect a significant proportion of cytogenetically normal LTC-IC in the same specimen. In fact, the concentration of these apparently normal LTC-IC in the blood of newly diagnosed patients with AML was 10-to greater than 1000-fold higher than the concentration we had earlier detected in normal steady-state blood using similar assay conditions. 4 We had previously determined that more than 90% of AML blast samples, including those with inv(16), respond to the cytokines G-CSF, IL-3, Steel Factor (SF) and/or fit-3 ligand (FL) as demonstrated by formation in methylcellulose. To determine if the more primitive AML LTC-IC would also respond to these factors, LTCs of AML cells were supplemented with one or more of these cytokines either in the form of murine feeders engineered to constitutively produce human growth factors or by the repeated addition of cytokine(s) to LTC. As compared to control LTC with human marrow feeders, the output of CFC from 5-week-old cytokine-supplemented LTC more than doubled for eight of the nine AML samples. The relative proportions of cytogenetically normal and abnormal CFC remained relatively constant in most, but not all, of these cultures. In particular, the largest increases in CFC output (up to 500-fold as compared to control LTC) were seen in co-cultures of AML cells from patients with inv(16) supplemented with FL and/or murine feeders, some of which had been engineered to produce G-CSF, IL-3 and SF. However, in these LTC the proportion of CFC containing inv(16) decreased substantially, in some cases to the point where only cytogenetically normal CFC could be detected at 5 weeks, indicating that most, if not all, of the increased CFC output was generated by the cytogenetically normal LTC-IC present in the original sample. The G-CSF, IL-3 and SF-producing murine feeders used in these experiments were those which we had previously selected for their ability to enhance the sensitivity with which normal blood and marrow LTC-ICs could be detected. 3 Thus, the different responses to these feeders of the cytogenetically normal and abnormal LTC-IC in AML peripheral blood coupled with the reliability of the inv(16) FISH probe that we used to distinguish these populations suggests that the cytogenetically normal LTC-IC in these samples were in fact truly normal. This further suggests that normal hematopoiesis may be relatively well-preserved even in newly diagnosed patients with inv(16) AML. 1 Among a variety of different immunodeficient mouse strains which we and others have evaluated, nonobese diabetic (NOD)/SCID mice 5 appear to be the most useful for allowing the engraftment and detection of human AML progenitors. 2, 6 Approximately 60% of different AML samples will engraft in these animals as detected by the presence of more than 1% human AML cells in mouse bone marrow 8 weeks postintravenous injection of 10 7 cells per mouse. At limiting dilution the frequency of SL-IC has been found to be 100-to 1000-fold lower than that of AML LTC-IC in the same patient sample suggesting either that SL-IC represent a more rare progenitor cell type or that the SL-IC assay is not yet sensitive enough to detect all the cells capable of demonstrating similar functional properties. In contrast to our experience with adding cytokines to LCT of AML cells, attempts to increase the levels of engraftment of leukemic cells in mice by injecting the animals i.p. three times weekly with human growth factors have so far been generally unsuccessful.
Eight samples from patients with inv(16) AML have been injected into NOD/SCID mice with engraftment of the leukemic cells detected 8 weeks later for six of these eight. However, the levels of engraftment detected are on average lower than those seen in mice injected with cells from patients with AML with cytogenetic abnormalities associated with a poor prognosis (eg rearrangement of 11q23). This suggests that subtypes of AML characterized by more aggressive clinical behavior may exhibit similar properties in mice. Thus, NOD/SCID mice may ultimately not only provide an assay system for detecting very primitive leukemic progenitors but may also be useful for preclinical testing of novel therapeutic strategies for human AML.
In summary, it is now possible to routinely detect and quantitate rare primitive progenitors among the malignant cells of patients with AML both in vitro and in vivo. By analogy with normal hematopoiesis it seems likely that at least a subset of these cells are leukemic 'stem cells' which maintain the malignant clone in human patients. If so, therapeutic strategies designed to exploit differences between these cells and their normal counterparts would hold particular promise for the future.
